**Additional file 2: Table S2. Structure and Content of the AGREE II instrument**

The following is adapted from the AGREE II instrument (Brouwers M C, Kho M E, Browman G P, et al. AGREE II: advancing guideline development, reporting and evaluation in health care[J]. Canadian Medical Association Journal, 2010, 182(18): E839-E842.)

|  |  |  |
| --- | --- | --- |
| **Domains**  | **Content**  | **No. of items** |
| Scope and purpose | Addresses the overall aim of the guideline, the specific clinical questions and targets patient population | 3 |
| Stakeholder involvement | Addresses the extent to which the guideline represents the views of its intended users (relevant professional groups, patients, target users defined, piloting among target users) | 3 |
| Rigor of development | Addresses the process used to collect and synthesize the evidence, the methods to formulate the recommendations, process for updating the guidelines, external review | 8 |
| Clarity and presentation | Addresses the language and format of the guideline (recommendations are specific and unambiguous, different options for management are presented, key recommendations are identifiable, tools for application are available) | 3 |
| Applicability  | Addresses the likely organisational, behavioral, and cost implications of applying the guideline, key criteria for monitoring and/or audit purposes | 4 |
| Editorial independence | Addresses the independence of the recommendations and acknowledgement of possible conflict of interest from the guideline development group  | 2 |